CIK 0001645113
- Large accelerated filer
NovoCure Ltd
Sign in to watch- Ticker
- NVCR
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +44 1534756700
- Business address
- NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Jersey
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $142,786
- in 3 filings
Net −$142,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | LEUNG GABRIEL Director | Grant or award | +4,053 | 83,192 | ||
| 2024-06-05 | LEUNG GABRIEL Director | Grant or award · Stock Option (Right to Buy) | +6,229 | 6,229 | ||
| 2024-06-05 | HILLEMAN JERYL L Director | Grant or award | +4,053 | 6,590 | ||
| 2024-06-05 | HILLEMAN JERYL L Director | Grant or award · Stock Option (Right to Buy) | +6,229 | 6,229 | ||
| 2024-06-04 | VERNON W ANTHONY Director | Sale | −964 | $23.89 | $23K | 164,833 |
| 2024-06-04 | Scannell Timothy J Director | Sale | −964 | $23.89 | $23K | 2,964 |
| 2024-06-04 | LEUNG GABRIEL Director | Sale | −964 | $23.89 | $23K | 78,175 |
| 2024-03-04 | GROENHUYSEN WILHELMUS CM Chief Operating Officer | Sale | −1,217 | $16.01 | $19K | 251,235 |
| 2024-03-04 | Leonard Frank X EVP, Pres., Novocure Oncology | Sale | −840 | $16.01 | $13K | 160,098 |
| 2024-03-01 | GROENHUYSEN WILHELMUS CM Chief Operating Officer | Sale | −2,107 | $16.03 | $34K | 252,452 |
| 2024-03-01 | Leonard Frank X EVP, Pres., Novocure Oncology | Sale | −1,679 | $16.03 | $27K | 160,938 |
| 2024-02-28 | Leonard Frank X EVP, Pres., Novocure Oncology | Sale | −2,078 | $16.14 | $34K | 162,617 |
| 2024-02-28 | GROENHUYSEN WILHELMUS CM Chief Operating Officer | Sale | −2,303 | $16.14 | $37K | 254,559 |
| 2024-02-27 | Cordova Ashley Chief Financial Officer | Grant or award | +102,249 | $16.30 | $1.7M | 219,867 |
| 2024-02-27 | Cordova Ashley Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +156,348 | $16.30 | $2.5M | 156,348 |
| 2024-02-27 | Leonard Frank X EVP, Pres., Novocure Oncology | Grant or award | +102,249 | $16.30 | $1.7M | 164,695 |
| 2024-02-27 | Leonard Frank X EVP, Pres., Novocure Oncology | Grant or award · Stock Options (Right to buy) | +156,348 | $16.30 | $2.5M | 156,348 |
| 2024-02-27 | Puri Michal Nath Chief Human Resources Officer | Grant or award | +71,574 | $16.30 | $1.2M | 109,167 |
| 2024-02-27 | Puri Michal Nath Chief Human Resources Officer | Grant or award · Stock Options (Right to buy) | +109,443 | $16.30 | $1.8M | 109,443 |
| 2024-02-27 | Weinberg Uri Chief Innovation Officer | Grant or award | +81,799 | $16.30 | $1.3M | 171,148 |
Page 11 of 20 · 399 trades